ONCY
Oncolytics Biotech Inc
$0.89
-0.03 (-3.26%)
At close · Jul 10
Market Cap
$105.90M
Shares
119,354,067
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.89
Open$0.91
Day$0.87–0.92
52W$0.77–1.51
Avg vol 30d1.4M
Short int6.6M · 5.5% float · 5.9d
Short vol67%
Last earningsMar 31, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
+0%
above
RSI (14)
49
neutral
MACD trend
Negative
52-week position
16%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+11%
trailing
6-month return
−8%
trailing
YTD return
+2%
this year
Relative strength
−17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
5 of 59 funds reported for Jun 30 · net -35.1K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.54% of float · ▼ -7.2% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
59 holders — mid 3-yr range
Squeeze score
63
elevated · 0–100
Fundamentals
EPS growth
0%
Y/Y
Free cash flow
$-20.1M
Balance sheet
$5.2M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
+0%
Bullish
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
16%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
5 of 59 funds reported for Jun 30 · net -35.1K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.54% of float · ▼ -7.2% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
59 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 16%
52-wk high $2
vs 200-day avg -12%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ONCY
this stock
Oncolytics Biotech Inc
|
$105.90M | +2.3% | — | — | 5.5% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
56
- % held
- 3.2%
- Reported
- 5 of 59
- Top holder
- MARSHALL WACE, LLP
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ONCY | -1.1% | +11.3% | -8.3% | -6.3% | +2.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -2.5% | +7.2% | -17.3% | -7.4% | -8.4% |